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Abstract 
Background: Protein tyrosine kinase 6 (PTK6) is overexpressed in many epithelial tumors and predicts poor progno‑
sis. However, PTK6 expression status and its role in cervical squamous cell cancer are unknown. This study aimed to 
investigate the expression level and clinical significance of PTK6 in early‑stage cervical squamous cell cancer.
Methods: Quantitative reverse transcription‑polymerase chain reaction (qRT‑PCR) and western blotting analysis were 
performed to detect PTK6 mRNA and protein expression levels in 10 freshly frozen, early‑stage cervical squamous cell 
cancer specimens and adjacent non‑tumorous cervical tissues. The expression of PTK6 was detected using immuno‑
histochemical staining in 150 formalin‑fixed, paraffin‑embedded, early‑stage cervical squamous cell cancer sections 
and 10 normal cervical tissue sections.
Results: The mRNA and protein levels of PTK6 in cancer tissues were higher than those in adjacent non‑tumorous 
cervical tissues. Immunohistochemical analysis showed that PTK6 was not expressed in normal cervical tissues but 
was overexpressed in the cytoplasm of cervical squamous cell cancer cells. The level of PTK6 expression was signifi‑
cantly associated with tumor grade (P = 0.020). The 5‑year overall survival rate of patients with high PTK6 expression 
was lower than that of patients with low PTK6 expression (81.3% vs. 96.2%, P = 0.008). Multivariate Cox regression 
analysis showed that the expression level of PTK6 in cervical squamous cell cancer was an independent prognostic 
factor for patient survival (hazard ratio = 5.999, 95% confidence interval 1.622–22.191, P < 0.05).
Conclusions: PTK6 is overexpressed in cervical squamous cell cancer. Increased PTK6 expression is associated with 
reduced 5‑year overall survival. PTK6 expression is an independent prognostic predictor for cervical cancer.
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Background
Cervical cancer is the most common malignancy of the 
female genital tract worldwide and the second leading 
cause of cancer death in women. Approximately 275,000 
deaths due to cervical cancer occurred worldwide in 
2008, and approximately 85% of these cases occurred 
in developing countries [1]. The substantial decline of 
its incidence and mortality in developed countries was 
presumed to reflect the use of effective screening and 
anti-human papillomavirus (HPV) vaccines [2]. In 2011, 
there were an estimated 87,982 new cases in China, and 
the annual number of deaths was greater than 20,000 [3]. 
Approximately 75% of all cervical cancer patients have 
squamous cell carcinoma [4]; however, the incidence of 
cervical adenocarcinoma has increased in the past three 
decades [5]. The main treatment of early-stage disease 
is either a radical hysterectomy and pelvic lymph node 
dissection or radiotherapy; the main treatment of late-
stage disease is radiotherapy. Despite the improvement 
of surgical skill and radiotherapy methods, the 5-year 
survival rate for patients with late-stage disease remains 
unsatisfactory. Therefore, understanding the molecular 
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mechanisms of the early events of cervical cancer and 
searching for novel targets involved in the progression of 
cervical cancer is of great value for providing new thera-
peutic targets and improving patient survival.
Protein tyrosine kinase 6 (PTK6), also termed breast 
tumor kinase (Brk), was initially identified in a meta-
static breast tumor [6], subsequently cloned from mouse 
intestinal crypt cells and named Src-related intestinal 
kinase (Sik) [7]. PTK6 protein structure consists of the 
Src homology 3 (SH3) domain, Src homology 2 (SH2) 
domain, and catalytic domains, which structurally 
resemble the Src family of non-receptor protein tyrosine 
kinases. The most notable distinction between PTK6 and 
the SRC family kinases is the lack of myristoylation and 
palmitoylation sequences, which make intracellular local-
ization flexible. PTK6 has been implicated in a variety of 
tissues and cancers and is related to the regulation of dif-
ferent signaling pathways. A growing number of studies 
have revealed that the function of PTK6 depends on the 
cell type it is expressed in and its intracellular localiza-
tion. PTK6 is overexpressed in many epithelial tumors, 
including breast cancer [8], non-small cell lung cancer 
[9], and ovarian cancer [10], and is associated with poor 
patient survival. However, in other tumors, including 
nasopharyngeal carcinoma [11] and esophageal squa-
mous cell carcinoma [12], PTK6 may play an important 
anti-oncogenic role by regulating cell proliferation, dif-
ferentiation, and migration. The role that PTK6 plays in 
different tumors reveals its tissue specificity. Compared 
with the frequency of ErbB2 overexpression (25%–30%), 
the high frequency of PTK6 expression (60%–86%) in 
breast tumor cells suggests that this protein has great 
potential as a new therapeutic target, especially in 
patients with no ErbB2 expression. The expression level 
of PTK6 and its clinical relevance in cervical squamous 
cell cancer have not been studied. In this study, we inves-
tigated the expression level and clinical significance of 
PTK6 in early-stage cervical squamous cell cancer.
Methods
Patients and tissue specimens
The inclusion criteria for patients were as follows: (1) a 
pathologically confirmed diagnosis of cervical squamous 
cell cancer and an International Federation of Obstet-
rics and Gynecology (FIGO) stage between IB1 and IIB; 
(2) initial treatment including radical hysterectomy and 
bilateral pelvic lymph node dissection were performed at 
Sun Yat-sen University Cancer Center between January 
2009 and December 2011; (3) no preoperative anti-cancer 
therapy; and (4) no secondary cancer. Paraffin-embedded 
cervical squamous cell cancer specimens were obtained 
from the Pathology Department. Normal cervical epi-
thelial samples (to be used as normal controls) were 
collected from patients who had benign uterine tumors 
and needed a hysterectomy during the same period. 
Patients’ hospital records were reviewed to obtain demo-
graphic data, including age, serum level of squamous cell 
carcinoma (SCC) antigen, tumor size and stage, surgical 
procedures, pathologic report, adjuvant therapy, and fol-
low-up information.
Postoperative adjuvant radiotherapy was recom-
mended for patients with the following pathologic risk 
factors: positive lymph nodes, deep cervical stromal inva-
sion, positive margin, and/or lymphovascular space inva-
sion. Postoperative chemotherapy was recommended for 
patients with positive lymph nodes or lymphovascular 
space invasion. The sequential chemotherapy regimens 
were as follows: irinotecan at 60–80 mg/m2 on days 1 and 
8 or paclitaxel at 175 mg/m2 and cisplatin at 60–75 mg/
m2 on day 1. These doses were repeated every 3  weeks 
for 4 cycles. The concurrent chemotherapy regimen was 
cisplatin at a dose of 35–40  mg/m2 weekly during radi-
otherapy. The total radiation dose was approximately 
45–50  Gy with a fractionation of 1.8–2.0  Gy daily. The 
irradiation fields were mainly the pelvic cavity field with 
two exceptions of a para-aortic extended field.
Ten fresh cervical squamous cell cancer specimens 
(from 6 patients with FIGO stage IB1 tumor and 4 
patients with FIGO stage IIA1 tumor; 2, 3, and 5 of the 
10 patients had grade 3, 2, and 1 tumors, respectively) 
and their matched adjacent non-tumorous cervical tis-
sues were collected immediately after resection and were 
immersed in RNAlater (Ambion, Austin, TX, USA) to 
prevent RNA degradation. The samples were stored at 
4  °C overnight and then frozen at −80  °C before RNA 
and protein extraction for quantitative reverse transcrip-
tion polymerase chain reaction (qRT-PCR) and Western 
blotting analysis.
qRT‑PCR
Total RNA was extracted from frozen tissues using Tri-
zol reagent (Invitrogen, Carlsbad, CA, USA) in accord-
ance with the manufacturer’s instructions. A Nanodrop 
Spectrophotometer (ND-1000; Thermo Scientific, Wilm-
ington, DE, USA) was used to assess the concentration 
and quality of the extracted total RNA. According to the 
manufacturer’s instruction, cDNA was synthesized using 
2 μg RNA and M-MLV Reverse Transcriptase (Promega, 
Fitchburg, WI, USA). We used the ABI 7900HT Real-
time PCR system (Life Technologies, Carlsbad, CA, USA) 
to perform gene amplification with the following reac-
tion conditions: 94  °C for 5  min; 40 cycles at 94  °C for 
30 s, 58 °C for 30 s, and 72 °C for 50 s for primer exten-
sion; and 72 °C for 10 min. The housekeeping gene glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as an internal control. The primers for qRT-PCR 
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were designed using the primer 5.0 software (PRE-
MIER Biosoft International, Palo Alto, CA, USA) and 
had the following sequences: 5′-TACTTTGGGGAG 
GTCTTCGAG-3′ for forward PTK6 primer and 5′-TGC 
CGCAGCTTCTTCATG-3′ for reverse PTK6 primer; 
5′-CTCCTCCTGTTCGACAGTCAGC-3′ for forward 
GAPDH primer and 5′-CCCAATACGACCAAATC 
CGTT-3′ for reverse GAPDH primer. The comparative 
cycle threshold (Ct) value was measured and used for 
data analysis.
Western blotting analysis
Total protein was extracted from frozen samples using 
Radio-Immunoprecipitation Assay Lysis Buffer, and 
the total protein concentration was measured using the 
Bicinchoninic Acid Protein Assay Kit (Bio-Rad, Her-
cules, CA, USA). Proteins were separated by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) and then electro-transferred onto a poly-
vinylidene difluoride (PVDF) membrane (Bio-Rad). The 
blotted membranes were blocked in 5% skim milk diluted 
in phosphate buffer solution supplemented with 0.1% 
Tween (PBST) for 1 h. After blocking the macromolecu-
lar antigen, the blotted membranes were incubated with 
anti-rabbit PTK6 antibody (1:1000 dilution; Proteintech, 
Wuhan, Hubei, China) followed by horseradish peroxi-
dase (HRP)-conjugated secondary antibody (1:2000 dilu-
tion; Cell Signaling Technologies, Danvers, MA, USA) for 
1  h. GAPDH protein (1:2000 dilution; Proteintech) was 
used as a loading control.
Immunohistochemistry
Paraffin-embedded cervical squamous cell cancer 
specimens were cut into 5-mm thick sections and then 
dewaxed with xylene. After rehydration in gradient alco-
hol solutions, these sections were submerged in ethylene 
diamine tetraacetic acid (EDTA) buffer and microwaved 
in a cooker at high pressure for 12 min followed by low 
pressure for 13  min for antigen retrieval. To quench 
endogenous peroxidase and non-specific binding, these 
sections were incubated in 3% hydrogen peroxide for 
10  min followed by submergence in fetal bovine serum 
for 30 min at room temperature. The tissue sections were 
incubated with anti-PTK6 antibody (1:500 dilution) at 
4  °C overnight followed by HRP-conjugated secondary 
antibody after washing with phosphate-buffered saline 
(PBS) five times (5 min each time). Subsequently, the vis-
ualization signal was developed with diaminobenzidine 
tetrahydrochloride (DAB) for 1  min and counterstained 
with hematoxylin.
The results of immunohistochemical (IHC) staining 
were scored independently by two pathologists regard-
less of patients’ clinical features. The IHC score was 
determined by both staining intensity and proportion 
of positively stained cancer cells. Intensity of staining 
score was categorized as 0, no staining; 1, weak stain-
ing; 2, moderate staining; and 3, strong staining. The 
percentage of stained tumor cell was scored as 0, <10%; 
1,  ≥10% to  <25%; 2,  ≥25% to  <50%; 3,  ≥50% to  <75%; 
and 4, ≥75%. The final immunoreactivity score (IRS) was 
the product of staining intensity score and percentage 
score and ranged from 0 to 12. Cut-off values for PTK6 
expression were based on the median of all products. An 
optimal cut-off value was determined as follows: ≤6 indi-
cates low PTK6 expression, and >6 indicates high PTK6 
expression.
Statistical analysis
Statistical Product and Service Solutions (SPSS) software 
package (version 17.0, SPSS Inc., Chicago, IL, USA) was 
used to perform statistical analysis. The Chi square test or 
Fisher’s exact test was used to determine the relationship 
between PTK6 expression levels and the clinicopatho-
logic features of patients with cervical squamous cell can-
cer. Patients were followed up by either outpatient visit or 
telephone survey before January 31, 2015, and recurrence 
was diagnosed based on clinical and laboratory assess-
ments. The overall survival (OS) of patients was defined 
as the time from initial surgery until the date of death or 
the last follow-up. The progression-free survival (PFS) of 
patients was determined as the time from initial surgery 
to recurrence or progression. Kaplan–Meier analysis was 
employed to plot survival curves, and the log-rank test 
was used to compare the differences between the survival 
curves. The prognostic effects of clinicopathologic vari-
ables were identified by univariate and multivariate Cox 
proportional hazards regression analysis. A P < 0.05 was 
considered statistically significant.
Results
Clinical features of included patients with early‑stage 
cervical squamous cell cancer
A total of 150 patients were selected from our cancer 
center database between January 2006 and December 
2011. The median follow-up duration was 57  months 
(range, 17–100  months). The median patient age was 
45  years (range, 31–67  years). The numbers of patients 
with stage IB1, IB2, IIA1, and IIB disease were 99, 12, 
34, and 5, respectively. 6, 38, and 106 patients had grade 
1, 2, and 3 tumors, respectively. The metastasis rate of 
the pelvic lymph nodes was 27.3% (41/150) (Table  1). 
Eighty-one patients received postoperative pelvic radio-
therapy. Of the 81 patients, 49 received radiotherapy plus 
cisplatin-based chemotherapy (28 received sequential 
chemoradiotherapy, and 21 received concurrent chemo-
radiotherapy), and 32 received radiotherapy alone. Of 
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the total 150 patients, 4 received chemotherapy alone as 
postoperative adjuvant therapy.
PTK6 mRNA and protein expression levels in early‑stage 
cervical squamous cell cancer tissues
qRT-PCR results showed that the mRNA level of PTK6 
in cancer tissues was higher than that in adjacent non-
tumorous cervical tissues, and the range of fold increase 
was 3.6–11.9 (Fig. 1a). Similarly, Western blotting showed 
that the cancer tissues had higher levels of PTK6 protein 
expression compared with matched non-tumorous tis-
sues (Fig. 1b).
PTK6 protein expression in cervical cancer tissues 
and normal cervical epithelia
PTK6 expression levels were detected with IHC staining 
in 150 cervical cancer specimens and 10 normal cervi-
cal epithelia specimens (Fig.  2). Of the 150 patients, 69 
(46.0%) had high cytoplasmic PTK6 expression levels, 
and 81 (54.0%) showed low cytoplasmic expression lev-
els. No PTK6 protein expression was detected in the 10 
normal cervical epithelia samples.
Relationship between PTK6 expression 
and clinicopathologic characteristics of patients 
with early‑stage cervical squamous cell cancer
PTK6 expression was associated with tumor grade in 
patients with early-stage cervical squamous cell can-
cer (P =  0.020); no significant association was detected 
between PTK6 expression level and age, tumor size, 
FIGO stage, deep cervical stromal invasion, pelvic lymph 
node metastasis, SCC antigen level, and lymphovascular 
space invasion (all P > 0.05) (Table 1).
Association of PTK6 expression and patient survival
The 5-year OS rate of the 150 patients was 90.7%. The 
5-year OS rate was significantly lower in patients with 
high PTK6 expression than in those with low PTK6 
expression (81.3% vs. 96.2%, P  =  0.008) (Fig.  3a); the 
5-year DFS rate was similar between these two groups 
(79.7% vs. 81.5%, P = 0.834) (Fig. 3b).
Univariate Cox proportional hazard regression analysis 
indicated that FIGO stage (P = 0.002), pelvic lymph node 
metastasis (P  =  0.019), deep cervical stromal invasion 
(P =  0.028), lymphovascular space invasion (P < 0.001), 
and PTK6 expression (P  =  0.017) were significantly 
associated with OS of patients with early-stage cervi-
cal squamous cell cancer. Multivariate Cox proportional 
hazard regression analysis revealed that PTK6 expression 
(P = 0.007), FIGO stage (P = 0.001), and lymphovascular 
space invasion (P  <  0.001) were independent significant 
prognostic factors for OS (Table 2).
Discussion
In our study, we detected PTK6 expression in early-stage 
cervical squamous cell cancer and analyzed the relation-
ship between PTK6 expression and patients’ clinico-
pathologic characteristics. Our data indicated that both 
PTK6 mRNA and protein levels were elevated in cervi-
cal squamous cell cancer and the elevated cytoplasmic 
expression of PTK6 was associated with tumor grade and 
short patient survival. No PTK6 expression was observed 
in normal cervical epithelia. Furthermore, our results 
suggest that the PTK6 expression is an unfavorable inde-
pendent prognostic factor in patients with early-stage 
cervical squamous cell cancer.
Table 1 Relationships between  protein tyrosine kinase 6 
(PTK6) expression level and clinicopathologic characteris-
tics of the patients with early-stage squamous cervical cell 
cancer
SCC squamous cell carcinoma





χ2 value P value
High Low
Age (years) 0.172 0.679
 ≤45 81 36 (44.4) 45 (55.6)
 >45 69 33 (47.8) 36 (52.2)
Tumor size (cm) 0.842 0.359
 ≤4 138 65 (47.1) 73 (52.9)
 >4 12 4 (33.3) 8 (66.7)
Tumor grade 7.651 0.020*
 1 6 6 (100) 0 (0)
 2 38 18 (47.4) 20 (52.6)
 3 106 45 (42.5) 61 (57.5)
Clinical stage 3.484 0.323
 IB1 99 45 (45.5) 54 (54.5)
 IB2 12 4 (33.3) 8 (66.7)
 IIA1 34 19 (55.9) 15 (44.1)
 IIB 5 1 (20.0) 4 (80.0)
Pelvic lymph node 
metastasis
0.176 0.675
 Absent 109 49 (45.0) 60 (55.0)




 Absent 71 37 (52.1) 34 (47.9)
 Present 79 32 (40.5) 47 (59.5)
SCC antigen level 
(ng/mL)
3.671 0.055
 ≤1.5 99 40 (40.4) 59 (59.6)




 Absent 134 61 (45.5) 73 (54.5)
 Present 16 8 (50.0) 8 (50.0)
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The function of PTK6 in normal epithelia and in can-
cer is not fully understood. In normal epithelia, PTK6 is 
involved in cell differentiation, apoptosis, migration, and 
tissue repair. In cancer, the role of PTK6 remains contro-
versial. Some studies indicated that PTK6 may act as a 
tumor suppressor gene [12–14]. Liu et al. [13] found that 
PTK6 expression was lower in laryngeal squamous cell 
carcinoma tissues than in adjacent non-tumorous laryn-
geal epithelial tissues, as measured with Western blotting 
and RT-PCR. In patients with laryngeal squamous cell 
carcinoma, low expression of PTK6, as detected by IHC, 
was associated with short OS and DFS. Ma et  al. [14] 
demonstrated that PTK6 expression was significantly 
reduced in esophageal squamous cell carcinoma tissues 
and cell lines compared with non-tumorous tissues or 
immortalized normal esophageal cell lines. Overexpres-
sion of PTK6 in these cells reduced their proliferation in 
culture and tumor formation in mice.
However, most studies showed that PTK6 was a poten-
tial oncogene and played a role in tumorigenesis and 
tumor development. PTK6 was found to be overex-
pressed in breast cancer [8], non-small cell lung cancer 
[9], and ovarian cancer [10]. In vitro studies showed that 
PTK6 promoted tumor cell migration, invasion, and pro-
liferation [14, 15]. The underlying mechanism by which 
PTK6 works in cancer biology is gradually being revealed 
[15–21]. Park et  al. [22] demonstrated that PTK6 was 
involved in tumor cell apoptosis. Down-regulation of 
PTK6 induced apoptosis in lapatinib-resistant, Her2-
positive breast cancer cells by enhancing Bim expression 
[22]. Harvey et al. [16] demonstrated that PTK6 protected 
breast cancer cells from autophagic cell death induced by 
loss of adhesion. In our study, PTK6 was overexpressed in 
freshly frozen cervical squamous cell cancer specimens, 
and PTK6 protein was overexpressed in tumor tissues 
from 150 patients with cervical cancer. Thus, data from 
the literature and our study suggest that PTK6 may act as 
an oncogene in tumor initiation and progression.
The prognostic value of PTK6 in human malignancies 
was controversial. Studies on esophageal squamous cell 
carcinoma [12] and laryngeal squamous cell carcinoma 
[13] showed that low PTK6 expression was significantly 
associated with low 5-year OS rates for patients. In con-
trast, studies in other types of cancer, including breast 
cancer [23] and non-small cell lung cancer [24], showed 
that high PTK6 expression was significantly associated 
with low 5-year OS rates. Our study showed that PTK6 
overexpression was associated with short survival for 
patients with cervical cancer. We found that the 5-year 
OS rate of patients with high PTK6 expression was sig-
nificantly lower than that of patients with low PTK6 
expression (81.3% vs. 96.2%). Furthermore, the Cox pro-
portional hazard regression model revealed that PTK6 
expression was an independent prognostic factor for OS. 
Thus, our data suggest that PTK6 may be used as a prog-
nostic factor for cervical cancer.
Fig. 1 Quantitative reverse transcription‑polymerase chain reaction (qRT‑PCR) and western blotting analysis of protein tyrosine kinase 6 (PTK6) 
expression in early‑stage cervical squamous cell cancer tissues. a qRT‑PCR analysis of PTK6 mRNA expression in early‑stage cervical squamous cell 
cancer tissues. The mRNA level of PTK6 in cancer tissues (T) is higher than that in paired adjacent non‑tumorous cervical tissues (N), and the range 
of fold increase (average T/N ratio) was 3.6–11.9. b Western blotting analysis of PTK6 protein expression in early‑stage cervical squamous cell cancer 
tissues. The protein level of PTK6 in 10 cervical squamous cell cancer tissues (T) was higher than that in paired adjacent non‑tumorous cervical tis‑
sues (N). Glyceraldehyde‑3‑phosphate dehydrogenase (GAPDH) was used as the loading control
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The function of PTK6 appears to be highly context- 
and cell type-specific. In normal epithelial cells, nuclear 
PTK6 expression is related to the regulation of cell 
growth, whereas cytoplasmic PTK6 expression may pro-
mote tumorigenesis by activating oncogenic signaling 
pathways in tumor cells [17, 25]. Intracellular localiza-
tion of PTK6 may determine the outcomes of the PTK6 
signaling [26]. In the SW620 colorectal adenocarcinoma 
cell line, targeting nuclear PTK6 negatively regulated 
endogenous β-catenin/T cell factor (TCF) transcrip-
tional activity, whereas targeting membrane PTK6 
enhanced β-catenin/TCF-regulated transcription [26]. 
In different cancers, the intracellular location of PTK6 
may be different [26]. PTK6 expression was observed 
on the plasma membrane in human breast tumors and 
in cell nuclei in well-differentiated prostate tumors [25]. 
Different types of cross-talk between signaling pathways 
and PTK6 may exist, which lead to a different PTK6 
function. Thus, further studies are needed for a better 
understanding of the role of PTK6 in cancer biology.
In conclusion, we demonstrated that PTK6 was over-
expressed in cervical squamous cell cancer and that high 
PTK6 expression was associated with short OS. PTK6 
expression may be an independent prognostic predictor 
of cervical cancer.
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